Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Latest From Sonoma Pharmaceuticals, Inc.

A Passion For Patient Care And De-Risking Disruptive Technologies

Biomedical engineering graduate Cécile Dupont has for the past 12 years helped healthcare technology businesses develop disruptive solutions that positively impact patients’ lives. The current chapter of her career opened in 2017 when she joined Sofinnova MD Start, the early-stage medtech incubator of VC investor Sofinnova Partners, where she is a partner.

Rising Leaders Innovation

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.

Financing Artificial Intelligence

French Market: Scale-Up Problems Are Preventing Start-Ups From Flourishing

Better medtech industry-government dialog is needed to improve the adoption of innovative medical devices by the French health care system. The current pathway is not obvious or easy, according to local manufacturers.

France Commercial

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Commercial Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Oculus Technologies Of Mexico, S.A. De C.V., Nvn Therapeutics, Oculus Innovative Sciences Netherlands B.V.
UsernamePublicRestriction

Register